Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Abstract Background Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-022-02844-z |
| _version_ | 1811171516797157376 |
|---|---|
| author | Yuki Kojima Kazuki Sudo Hiroshi Yoshida Shu Yazaki Momoko Tokura Chiharu Mizoguchi Hitomi S. Okuma Shosuke Kita Kasumi Yamamoto Tadaaki Nishikawa Emi Noguchi Tatsunori Shimoi Yasuhito Tanase Masaya Uno Mitsuya Ishikawa Tomoyasu Kato Kumiko Koyama Maki Kobayashi Tomoya Kakegawa Yasuhiro Fujiwara Kan Yonemori |
| author_facet | Yuki Kojima Kazuki Sudo Hiroshi Yoshida Shu Yazaki Momoko Tokura Chiharu Mizoguchi Hitomi S. Okuma Shosuke Kita Kasumi Yamamoto Tadaaki Nishikawa Emi Noguchi Tatsunori Shimoi Yasuhito Tanase Masaya Uno Mitsuya Ishikawa Tomoyasu Kato Kumiko Koyama Maki Kobayashi Tomoya Kakegawa Yasuhiro Fujiwara Kan Yonemori |
| author_sort | Yuki Kojima |
| collection | DOAJ |
| description | Abstract Background Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes in tumor tissue at recurrence. Therefore, this study aimed to evaluate the changes in HER3 expression between primary and recurrent status in gynecological cancers. Methods This retrospective study used matched-pair tissues of gynecological cancer patients at initial diagnosis and at recurrence. Immunohistochemical (IHC) scores of 3 + or 2 + were termed “HER3-high”, while IHC scores of 1 + or 0 were designated as “HER3-low/zero”. Results A total of 86 patients (40 with ovarian cancers, 32 with endometrial cancers, and 14 with cervical cancers) were included in this study. In ovarian cancer, 67.5% and 80.0% of the patients received a HER3-high at initial and recurrent diagnosis, respectively. The H-score was significantly increased at recurrence (p = 0.004). The proportion of HER3-high endometrial cancer patients increased from 46.9% at initial diagnosis to 68.8% at recurrence, and the H-score tended to increase at recurrence (p = 0.08). The fraction of HER3-high-rated cervical cancer patients remained unchanged at 85.7% both at initial and recurrent diagnosis. The discordance rate of HER3 expression detection in initial and recurrent diagnosis samples was 27.5%, 53.1%, and 14.3% for ovarian, endometrial, and cervical cancers, respectively. Ovarian and endometrial cancers with a HER3-high recurrent score tended to show shorter median survival time than those with a HER3-low/zero recurrent rating. Conclusion Our findings suggest that, in main types of gynecological cancers, the proportion of patients having a HER3-high score increased from initial to recurrent diagnosis. |
| first_indexed | 2024-04-10T17:16:21Z |
| format | Article |
| id | doaj.art-906d68d622e2442285a457d155246fd0 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-04-10T17:16:21Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-906d68d622e2442285a457d155246fd02023-02-05T12:24:29ZengBMCCancer Cell International1475-28672023-02-012311910.1186/s12935-022-02844-zChanges in HER3 expression profiles between primary and recurrent gynecological cancersYuki Kojima0Kazuki Sudo1Hiroshi Yoshida2Shu Yazaki3Momoko Tokura4Chiharu Mizoguchi5Hitomi S. Okuma6Shosuke Kita7Kasumi Yamamoto8Tadaaki Nishikawa9Emi Noguchi10Tatsunori Shimoi11Yasuhito Tanase12Masaya Uno13Mitsuya Ishikawa14Tomoyasu Kato15Kumiko Koyama16Maki Kobayashi17Tomoya Kakegawa18Yasuhiro Fujiwara19Kan Yonemori20Department of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Diagnostic Pathology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalDepartment of Gynecology, National Cancer Center HospitalDepartment of Gynecology, National Cancer Center HospitalDepartment of Gynecology, National Cancer Center HospitalDepartment of Gynecology, National Cancer Center HospitalTranslational Science Department I, Daiichi Sankyo Co., Ltd.Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd.Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd.Department of Medical Oncology, National Cancer Center HospitalDepartment of Medical Oncology, National Cancer Center HospitalAbstract Background Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes in tumor tissue at recurrence. Therefore, this study aimed to evaluate the changes in HER3 expression between primary and recurrent status in gynecological cancers. Methods This retrospective study used matched-pair tissues of gynecological cancer patients at initial diagnosis and at recurrence. Immunohistochemical (IHC) scores of 3 + or 2 + were termed “HER3-high”, while IHC scores of 1 + or 0 were designated as “HER3-low/zero”. Results A total of 86 patients (40 with ovarian cancers, 32 with endometrial cancers, and 14 with cervical cancers) were included in this study. In ovarian cancer, 67.5% and 80.0% of the patients received a HER3-high at initial and recurrent diagnosis, respectively. The H-score was significantly increased at recurrence (p = 0.004). The proportion of HER3-high endometrial cancer patients increased from 46.9% at initial diagnosis to 68.8% at recurrence, and the H-score tended to increase at recurrence (p = 0.08). The fraction of HER3-high-rated cervical cancer patients remained unchanged at 85.7% both at initial and recurrent diagnosis. The discordance rate of HER3 expression detection in initial and recurrent diagnosis samples was 27.5%, 53.1%, and 14.3% for ovarian, endometrial, and cervical cancers, respectively. Ovarian and endometrial cancers with a HER3-high recurrent score tended to show shorter median survival time than those with a HER3-low/zero recurrent rating. Conclusion Our findings suggest that, in main types of gynecological cancers, the proportion of patients having a HER3-high score increased from initial to recurrent diagnosis.https://doi.org/10.1186/s12935-022-02844-zHER3Ovarian cancerEndometrial cancerCervical cancer; biomarker |
| spellingShingle | Yuki Kojima Kazuki Sudo Hiroshi Yoshida Shu Yazaki Momoko Tokura Chiharu Mizoguchi Hitomi S. Okuma Shosuke Kita Kasumi Yamamoto Tadaaki Nishikawa Emi Noguchi Tatsunori Shimoi Yasuhito Tanase Masaya Uno Mitsuya Ishikawa Tomoyasu Kato Kumiko Koyama Maki Kobayashi Tomoya Kakegawa Yasuhiro Fujiwara Kan Yonemori Changes in HER3 expression profiles between primary and recurrent gynecological cancers Cancer Cell International HER3 Ovarian cancer Endometrial cancer Cervical cancer; biomarker |
| title | Changes in HER3 expression profiles between primary and recurrent gynecological cancers |
| title_full | Changes in HER3 expression profiles between primary and recurrent gynecological cancers |
| title_fullStr | Changes in HER3 expression profiles between primary and recurrent gynecological cancers |
| title_full_unstemmed | Changes in HER3 expression profiles between primary and recurrent gynecological cancers |
| title_short | Changes in HER3 expression profiles between primary and recurrent gynecological cancers |
| title_sort | changes in her3 expression profiles between primary and recurrent gynecological cancers |
| topic | HER3 Ovarian cancer Endometrial cancer Cervical cancer; biomarker |
| url | https://doi.org/10.1186/s12935-022-02844-z |
| work_keys_str_mv | AT yukikojima changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT kazukisudo changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT hiroshiyoshida changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT shuyazaki changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT momokotokura changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT chiharumizoguchi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT hitomisokuma changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT shosukekita changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT kasumiyamamoto changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT tadaakinishikawa changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT eminoguchi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT tatsunorishimoi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT yasuhitotanase changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT masayauno changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT mitsuyaishikawa changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT tomoyasukato changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT kumikokoyama changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT makikobayashi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT tomoyakakegawa changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT yasuhirofujiwara changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers AT kanyonemori changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers |